Country: Malta
Language: English
Source: Medicines Authority
NeoFarma Pharmaceuticals Limited 42-46, Mill Street, Qormi, QRM 3105, Malta
J01FA09
CLARITHROMYCIN 500 mg
PROLONGED-RELEASE TABLET
CLARITHROMYCIN 500 mg
POM
ANTIBACTERIALS FOR SYSTEMIC USE
Licence number in the source country: Romania - 9268/2016/01-02-03
Authorised
2024-02-16
Package leaflet: Information for the patient FROMILID UNO 500 MG PROLONGED-RELEASE TABLETS CLARITHROMYCIN Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Fromilid uno is and what it is used for 2. What you need to know before you take Fromilid uno 3. How to take Fromilid uno 4. Possible side effects 5. How to store Fromilid uno 6. Contents of the pack and other information 1. WHAT FROMILID UNO IS AND WHAT IT IS USED FOR Fromilid uno is an antibiotic from the group of macrolides. It acts by stopping the growth of bacteria that cause infections in the human body. Fromilid uno is indicated for the treatment of respiratory tract infections (e.g. infections of the sinuses, throat, tonsils, bronchi and lungs), and skin and subcutaneous tissue infections. Fromilid uno is used in adults and children 12 years of age and older. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FROMILID UNO DO NOT TAKE FROMILID UNO - if you are allergic to clarithromycin or any of the other ingredients of this medicine (listed in section 6), or other macrolide antibiotics; - if you have low blood potassium or magnesium levels (hypokalaemia or hypomagnesaemia); - if you have very severe liver impairment and kidney problems at the same time; - if you are taking oral midazolam (a sedative); - if you are taking medicines for high cholesterol (such as lovastatin or simvastatin); - if you are taking a medicine containing lomitapide; - if you have or someone in your family has heart rhythm disorders (ventricular cardiac arrhythmia, includ Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fromilid uno 500 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 500 mg clarithromycin. Excipients with known effect: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet The tablets are brownish yellow, oval, biconvex, film-coated and imprinted with U on one side. Tablet dimension: 20 x 10 mm 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Upper respiratory tract infections (e.g. tonsillopharyngitis, acute sinusitis). Lower respiratory tract infections (e.g. acute bacterial bronchitis, acute exacerbation of chronic bronchitis, and pneumonia). Skin and subcutaneous tissue infections. Fromilid uno is indicated in adults and children 12 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults and children over 12 years usually take one 500 mg tablet every 24 hours. In more severe infections, two 500 mg tablets should be taken every 24 hours. The usual duration of treatment is 6 to 14 days. Paediatric population _Children under 12 years of age _ Clinical trials have been conducted using clarithromycin suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin granules for oral suspension. _Renal impairment _ lactose 213.75 mg/tablet sodium 12.85 mg/tablet In patients with renal impairment with creatinine clearance less than 30 ml/min, the dosage of clarithromycin should be reduced by one half, i.e. 250 mg once daily, or 250 mg twice daily in more severe infections. Treatment should not be continued beyond 14 days in these patients. Because the prolonged-release tablet cannot be split, the dose cannot be reduced from 500 mg daily and this pharmaceutical form should not be used in this patient population (see section 4.3). Method of administration Oral use. The tabl Read the complete document